Format

Send to

Choose Destination
See comment in PubMed Commons below
Nanomedicine. 2014 Jan;10(1):119-29. doi: 10.1016/j.nano.2013.06.015. Epub 2013 Jul 24.

Nanoscale artificial antigen presenting cells for T cell immunotherapy.

Author information

  • 1Department of Biomedical Engineering, Johns Hopkins School of Medicine, Baltimore, MD, USA; Departments of Pathology, Oncology, and Medicine. Institute of Cell Engineering, Johns Hopkins School of Medicine, Baltimore, MD, USA.
  • 2Departments of Pathology, Oncology, and Medicine. Institute of Cell Engineering, Johns Hopkins School of Medicine, Baltimore, MD, USA.
  • 3Miltenyi Biotec, Bergisch Gladbach, Germany.
  • 4Department of Biology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
  • 5Departments of Pathology, Oncology, and Medicine. Institute of Cell Engineering, Johns Hopkins School of Medicine, Baltimore, MD, USA. Electronic address: jschnec1@jhmi.edu.

Abstract

Artificial antigen presenting cells (aAPC), which deliver stimulatory signals to cytotoxic lymphocytes, are a powerful tool for both adoptive and active immunotherapy. Thus far, aAPC have been synthesized by coupling T cell activating proteins such as CD3 or MHC-peptide to micron-sized beads. Nanoscale platforms have different trafficking and biophysical interaction properties and may allow development of new immunotherapeutic strategies. We therefore manufactured aAPC based on two types of nanoscale particle platforms: biocompatible iron-dextran paramagnetic particles (50-100 nm in diameter) and avidin-coated quantum dot nanocrystals (~30 nm). Nanoscale aAPC induced antigen-specific T cell proliferation from mouse splenocytes and human peripheral blood T cells. When injected in vivo, both iron-dextran particles and quantum dot nanocrystals enhanced tumor rejection in a subcutaneous mouse melanoma model. This is the first description of nanoscale aAPC that induce antigen-specific T cell proliferation in vitro and lead to effective T cell stimulation and inhibition of tumor growth in vivo.

FROM THE CLINICAL EDITOR:

Artifical antigen presenting cells could revolutionize the field of cancer-directed immunotherapy. This team of investigators have manufactured two types of nanoscale particle platform-based aAPCs and demonstrates that both iron-dextran particles and quantum dot nanocrystals enhance tumor rejection in a melanoma model, providing the first description of nanoscale aAPCs that lead to effective T cell stimulation and inhibition of tumor growth.

KEYWORDS:

Artificial antigen presenting cell; Immunotherapy; Nanoparticle; T cell

PMID:
23891987
PMCID:
PMC4114774
DOI:
10.1016/j.nano.2013.06.015
[PubMed - indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Support Center